A Phase 1 Open Label Dose Escalation Study Evaluate The Safety Of a Single Escalating Dose Of NX-CP105 (Human Adult Bone Marrow Derived Somatic Cells [hABM-SC] Administered by Endomyocardial Injection To Cohorts Of Adults 30-60 Days Following Acute Myocardial Infarction

Certain types of cells located in bone marrow may help the body recover after an injury. These cells may be able to help the body repair heart muscle that has been damaged from a heart attack. NX-CP105 is a new investigational drug that is made up of these special types of bone marrow cells, which come from another person. NX-CP105 has not been approved for sale or general use by the Food and Drug Administration (FDA), and this study will be the first time that NX-CP105 is given to human beings.
This study is being conducted to see if there are any side effects associated with with NX-CP105 and whether NX-CP105 may help the body repair heart muscle that has been damaged from a heart attack. Three different doses of NX CP105 will be tested in this study, starting with the lowest dose first.
Patients who decided to participate in the study will have a heart catheterization procedure during which a narrow tube is inserted into an artery (type of blood vessel) in the groin and passed to the heart. A second narrow tube will be inserted into a vein (type of blood vessel) in the groin and passed to your heart. A device will be passed through the second tube. This device will be used to inject NX-CP105 cells directly into your heart muscle.

开始日期2006-04-01

申办/合作机构

Neuronyx, Inc.

100 项与 Neuronyx, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Neuronyx, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Neuronyx, Inc. 相关的文献（医药）

2006-06-01·Neurorehabilitation and Neural Repair1区 · 医学

Recovery of Function Following Grafting of Human Bone Marrow-Derived Stromal Cells into the Injured Spinal Cord

1区 · 医学

Article

作者: Kopen, Gene C. ; Kushner, Robert ; Fischer, Itzhak ; Himes, B. Timothy ; Shumsky, Jed S. ; Coleman, Carl ; Neuhuber, Birgit ; Wagner, Joseph ; Swanger, Sharon A.

This study evaluates functional recovery after transplanting human bone marrow-derived stromal cells (BMSCs) into contusion models of spinal cord injury (SCI). The authors used a high-throughput process to expand BMSCs and characterized them by flow cytometry, ELISA, and gene expression. They found that BMSCs secrete neurotrophic factors and cytokines with therapeutic potential for cell survival and axon growth. In adult immune-suppressed rats, mild, moderate, or severe contusions were generated using the MASCIS impactor. One week following injury, 0.5 to 1 × 106 BMSCs were injected into the lesioned spinal cord; control animals received vehicle injection. Biweekly behavioral tests included the Basso, Beattie, and Bresnahan Locomotor Rating Scale (BBB), exploratory rearing, grid walking, and thermal sensitivity. Animals receiving moderate contusions followed by BMSC grafts showed significant behavioral recovery in BBB and rearing tests when compared to controls. Animals receiving BMSC grafts after mild or severe contusion showed trends toward improved recovery. Immunocytochemistry identified numerous axons passing through the injury in animals with BMSC grafts but few in controls. BMSCS were detected at 2 weeks after transplantation; however, at 11 weeks very few grafted cells remained. The authors conclude that BMSCs show potential for repairing SCI. However, the use of carefully characterized BMSCs improved transplantation protocols ensuring BMSC, survival, and systematic motor and sensory behavioral testing to identify robust recovery is imperative for further improvement.

2001-09-01·STEM CELLS2区 · 医学

MicroSAGE Analysis of 2,353 Expressed Genes in a Single Cell‐Derived Colony of Undifferentiated Human Mesenchymal Stem Cells Reveals mRNAs of Multiple Cell Lineages

2区 · 医学

Article

作者: DiGirolamo, Carla ; Tremain, Nicola ; Korkko, Jarmo ; Ibberson, David ; Phinney, Donald G. ; Kopen, Gene C.

Mesenchymal stem cells (MSCs) isolated from the bone marrow of adult organisms are capable of differentiating into adipocytes, chondrocytes, myoblasts, osteoblasts, and hematopoiesis-supporting stroma. We recently demonstrated that MSCs also adopt glial cell fates when transplanted into the developing central nervous system and hence can produce tissue elements derived from a separate embryonic layer. Despite these remarkable properties, it has been difficult to establish specific criteria to characterize MSCs. Using a modified protocol for micro-serial analysis of gene expression, we cataloged 2,353 unique genes expressed by a single cell-derived colony of undifferentiated human MSCs. This analysis revealed that the MSC colony simultaneously expressed transcripts characteristic of various mesenchymal cell lineages including chondrocytes, myoblasts, osteoblasts, and hematopoiesis-supporting stroma. Therefore, the profile of expressed transcripts reflects the developmental potential of the cells. Additionally, the MSC colony expressed mRNAs characteristic of endothelial, epithelial and neuronal cell lineages, a combination that provides a unique molecular signature for the cells. Other expressed transcripts included various products involved in wound repair as well as several neurotrophic factors. A total of 268 novel transcripts were also identified, one of which is the most abundantly expressed mRNA in MSCs. This study represents the first extensive gene expression analysis of MSCs and as such reveals new insight into the biology, ontogeny, and in vivo function of the cells.

项与 Neuronyx, Inc. 相关的新闻（医药）

2024-02-02

·同写意

尧唐生物宣布正式任命Tony W. Ho博士为科学顾问丨会员动态

细胞疗法基因疗法高管变更免疫疗法

2022-10-21

·Endpoints

Former Allergan exec heads to Revance as it challenges Botox; Mark Pruzanski surrounds himself with more teammates

→ Revance feels like it has a competitive advantage over AbbVie ’s blockbuster Botox with only biannual injections of its freshly approved Daxxify , as opposed to the injections every three or four months that Botox requires. But you come at the king, you best not miss, and as Daxxify hits the market, Revance has now tapped David Hollander as CMO. Hollander was previously the chief R&D officer at Aerie Pharmaceuticals , which was sold to Alcon a couple months ago in a $770 million deal , and he has familiarity with the Botox developer through his 10 years at Allergan . From 2011-16, he was Allergan’s VP, global therapeutic area head in clinical development for anterior segment and consumer eye care. The Nashville biotech is also testing DaxibotulinumtoxinA in patients with cervical dystonia, among other conditions. → Now under the leadership of ex- Intercept CEO Mark Pruzanski and part of this year’s Endpoints 11 class , obesity startup Versanis Bio has welcomed Kenneth Attie as CMO and Aditya Venugopal as SVP, corporate development and strategic planning. Attie was one of the staffers left out in the cold at Imara as it whittled down to a six-person company in April but turned around its fortunes by reverse merging with Enliven Therapeutics last week. Before he was Imara’s medical chief, Attie spent 11 years at Acceleron as VP, medical research. In a mini-reunion, Venugopal worked for Pruzanski at Intercept as head of strategic planning, and since 2020 he had been VP of business development for Luca Santarelli at VectivBio . → Wholesale changes are being made at Scynexis , and not just with a slimmed-down pipeline as it shops around for a commercialization partner with Brexafemme . CEO Marco Taglietti will retire on Dec. 31, setting up CMO David Angulo to replace him as we ring in 2023. Ex- Eisai and Athersys finance chief Ivor Macleod ’s first day as CFO will be Oct. 24, while chief commercial officer Christine Coyne ’s job has been phased out. Scynexis will also be making more cuts to a staff that stood at 56 employees as of March 1, but the exact number wasn’t revealed. Kyle LaHucik has more on a company in flux . → Lyn Baranowski has taken over for Bruce Montgomery as CEO of Seattle-based pulmonary disease outfit Avalyn Pharma , once known as Genoa Pharmaceuticals . Since 2018, Baranowski knows the pulmonary space well from her four years as operations chief at Altavant , and from 2013-18, the Novartis alum was SVP of corporate development & strategy with Melinta Therapeutics . Avalyn’s lead program is an inhaled version of pirfenidone named AP01 for idiopathic pulmonary fibrosis. → The CEO situation has taken a turn at Maravai LifeSciences , where former Danaher SVP Trey Martin had succeeded Carl Hull earlier this month — or so we thought. Three Danaher subsidiaries have a bone to pick with the appointment, suing Martin and Maravai , and “alleging that Martin is in breach of a noncompetition agreement.” With a temporary restraining order in place, Hull didn’t hide his displeasure as he retakes his old position. “We have complete confidence in Trey and are appalled that Danaher would seek to leverage a noncompetition agreement to prevent Trey from advancing his career,” Hull said in a statement. → Alice Zhang ’s AI drug discovery shop Verge Genomics has installed 14-year Biogen vet John Applegate as CFO. Formerly the VP of finance & accounting with Valo Health , Applegate closed out his Biogen career in 2019 as head of R&D finance. Zhang just contributed to Ochre Bio ’s $30 million Series A , while Verge’s latest round of funding totaled $98 million in December 2021 . In another Biogen connection, ex-R&D chief and current Voyager CEO Al Sandrock joined the board of directors at Verge in February. → Zentalis Pharmaceuticals has been relentless with its leadership moves since the Kim Blackwell era began in May with a $200 million cash infusion , promoting co-founders Cam Gallagher and Kevin Bunker while picking up a CMO and general counsel in that span. This week Zentalis returns to Peer Review with Mark Lackner as chief translational officer, head of biomarker strategy. Before he was head of biology and translational sciences for Ideaya Biosciences , Lackner led the oncology early-stage biomarker group as part of his 13 years at Genentech . → Co-founded and chaired by Tillman Gerngross , oncology outfit Ankyra Therapeutics has recruited Joseph Elassal as CMO. Elassal has two stints at Regeneron on his résumé: one from 2012-18, and the other as senior medical director, global medical affairs, oncology since 2020. In between, he was a deputy VP at PhRMA and a senior medical director for Replimune . Ankyra bagged a $45 million Series B in November 2021 with the help of Polaris , GV and a number of other investors. → Another Gerngross company, Invivyd , came out swinging when it was known as Adagio , with big aspirations for its Covid-19 monoclonal antibody along with bigger bucks. But the drug struck out against Omicron , and Gerngross was gone as CEO within a couple months. The name changed to Invivyd a few weeks ago, but the unease remains the same, as CFO/CBO Jane Henderson and chief commercial officer Eric Kimble have packed their bags. Fred Driscoll , a CFO with Renovacor , Flexion Therapeutics and Novavax , will bridge the gap as interim finance chief as Invivyd also says goodbye to an unspecified number of staffers. → Pittsburgh’s NeuBase Therapeutics has also been beset by layoffs, dismissing 60% of its employees this week while pivoting to gene editing. Sandra Rojas-Caro , NeuBase’s CMO since May 2021 who also began another role as head of R&D this past April, handed in her resignation. → As George Church ’s Colossal Biosciences continues its quest to bring back the woolly mammoth, its computational biology spinout Form Bio has locked in Mark Swendsen as chief revenue officer. Swendsen held the same position at DNAnexus before coming to Form Bio, which christened the boat with a $30 million Series A round in late September. → Flagship ’s Alltrna has dipped into the talent pool of the incubator’s most famous creation to find its VP, discovery platform. Caroline Köhrer comes to the tRNA player after more than two years as Moderna ’s director of RNA science — a key cog in the development of its Covid-19 vaccine — and five years overall. Alltrna chief Michelle Werner was part of Flagship’s rapid-fire CEO-partner appointments in April that included Margo Georgiadis and former AbbVie president Michael Severino . → While we have Flagship companies on our mind, Senda Biosciences has pulled in two new execs with the appointments of Lori Rudolph-Owen as COO and Barbara Bispham as general counsel. Rudolph-Owen hails from Goldfinch Bio , where she most recently served as chief development officer. Prior to that, Rudolph-Owen held a number of roles at Pfizer , AMAG Pharmaceuticals , MGI Pharma , Vertex and Millennium Pharmaceuticals . Bispham joins Senda from BridgeBio , where she was VP, head of legal. Prior to that, Bispham was with Goodwin Procter , Cooley and Reed Smith . → Not to be confused with the great basketball Hall of Famer Bob Pettit , Robert Petit has become the head of early clinical development at Orionis Biosciences , a cancer biotech that racked up $55 million in financing this week. Petit chairs the scientific advisory board and is the ex-CSO of Advaxis , which happened to make news the same day as Orionis’ raise by merging with Ayala Pharmaceuticals . One more thing about Orionis: Cormorant Asset Management founder and chief executive Bihua Chen is now a member of the board. → Nigel Horscroft has settled in as CSO of German antiviral biotech Atriva Therapeutics , replacing current scientific advisory board chairman Oliver Planz . Horscroft brings Big Pharma credentials with him from Pfizer, and during his time at CureVac from 2012-20, he was promoted to area head, molecular therapy. Atriva has also picked up two other clinical execs this year: Stephan Witte (VP, clinical science and operations) in January and Tim Overend (VP, clinical development and regulatory) in July. → Staying in Germany, Boehringer Ingelheim and GSK alum Thomas Bogenrieder has joined adenovirus-based cancer biotech Abalos Therapeutics as CMO. Bogenrieder had held the role of chief clinical officer at Swiss-based AMAL Therapeutics since July 2020 and is the ex-medical chief of Evaxion Biotech . A year ago around this time, Abalos topped off its Series A with $37.6 million in additional funding . → In September 2021, we told you about Roche vet Anja Harmeier taking the CEO job at Belgian remyelination biotech Rewind Therapeutics . Fast forward to this week, where Rewind has selected Irene Knuesel as CSO. Knuesel has Roche ties herself, closing out her six-year tenure in 2019 as the pharma giant’s head of the neuroimmunology and neurodegeneration section. Incidentally, Roche is under the microscope again in the Alzheimer’s space as we await data for its resuscitated drug gantenerumab . → Targeting solid tumors, Immuneering — one of many biotechs that took the Nasdaq plunge at the zenith of IPOs in 2021 — has brought in Leah Neufeld as chief people officer. Neufeld has worked in human resources for companies of all sizes, with J&J , Daiichi Sankyo and Prevail packing her résumé. The one-time head of HR at Intercept was recently the chief human resources officer for Jiangsu Hengrui subsidiary Luzsana Biotechnology . → Ashvattha Therapeutics , a hydroxyl dendrimer (HD) biotech based in the Bay Area, has pegged Steve Maricich as CMO. Maricich recently held the CMO post at Scripps ’ Calibr , and he’s been the medical chief at Allievex , the developer of a drug for Sanfilippo syndrome type B that was once in BioMarin ’s hands. → Jessica Atkinson has been appointed CBO of ImmuneID , a biotech out of Stephen Elledge ’s lab at Harvard that’s zeroing in on antibodies with its AI platform, called aiSPIRE. Atkinson rose to VP, business development at Foundation Medicine in 2019 after Roche’s $2.4 billion takeover , and she just had a brief run as SVP, business development of Glympse Bio . → Plainly-named IO Biotech , a Nasdaq newcomer in 2021 that’s going after IDO and PD-L1 with its cancer drugs IO102 and IO103 , has enlisted Amy Sullivan as CFO. Sullivan had a seat at the negotiating table as chief strategy officer of Kiadis when it was purchased by Sanofi for $358 million. The ex-SVP of corporate affairs at Keryx Biopharmaceuticals was also VP, investor relations and corporate communications with AMAG Pharmaceuticals. → Belgian biotech Bioxodes is changing up the top exec seat with the appointment of Marc Dechamps as CEO. Dechamps takes over the reins from company founder Edmond Godfroid , who is transitioning into the roles of COO and CSO. Dechamps brings with him experience from his times at GSK and ViiV Healthcare to the new role. → San Diego RNA editing biotech ADARx Pharmaceuticals is a busy bee in Peer Review too, naming Feriandas Greblikas as VP of clinical development after hiring CFO Chris Prentiss and CMC VP Christopher Claeboe this year. A veteran of Novo Nordisk , Biogen and Baxter , Greblikas comes to ADARx from Travere Therapeutics , where he was a senior medical director and clinical development lead. And in a previous gig, he worked for JJ Bienaimé as BioMarin’s medical director of phenylketonuria clinical trials. → Coming up on a year since its $60 million Series A , STAT3- and STAT6-focused Recludix Pharma is back in Peer Review with Paul Smith as SVP of biology. Smith, the ex-global research lead for Gilenya with Novartis, has also been senior director of inflammation and autoimmunity at Incyte . He held the role of VP, discovery biology at Connect Biopharma before pivoting to Recludix, a company out of San Diego that introduced CBO Matthew Caldemeyer in late September. → Transpacific oncology biotech AnHeart Therapeutics , which secured a $61 million Series B round last year, has welcomed aboard Heinrich Farin as senior medical director, clinical research and Michael Humphries as VP, head of US medical affairs. Farin hails from Mirati , where he served as senior medical director and has a prior stint as global senior medical director, clinical research and development at BeiGene . Earlier in his career, Farin had roles at Ariad Pharmaceuticals and Baxalta . Meanwhile, Humphries brings expertise from his time at Takeda Oncology , where he served as senior scientific director of global medical affairs. Prior to Takeda , Humphries had gigs at Bayer Healthcare Pharmaceuticals and Array Biopharma . → Swiss LILRB (leukocyte immunoglobulin-like receptor subfamily B) biotech ImmunOs Therapeutics has pegged Hilmar Ebersbach as VP, antibody development and protein engineering. Ebersbach had spent the last 15 years in biotherapeutic engineering and gene therapy at the Novartis Institutes for BioMedical Research . → Believe it or not, Daniel Ripley has ventured off to HighTide Therapeutics as SVP, business development. Ripley is an Ionis BD vet who led global business development for the last two years at Alpha Biopharma , and as the brave souls of HighTide give NASH a whirl with its lead program HTD1801 , he also has experience in the space as SVP of business development, program and alliance management at Conatus Pharmaceuticals , a Novartis partner plagued by NASH failures that merged with Histogen in 2020. → GSK India has named Bhushan Akshikar as managing director, succeeding Sridhar Venkatesh , who is transitioning to a senior role within the GSK Group. Akshikar joined GSK India in September 2011. Prior to GSK, Akshikar had a 15-year stint at J&J’s Janssen . → Ex-AMAG Pharmaceuticals CEO Brian Pereira has been named chairman at KalVista following the resignation of Martin Edwards and a resounding trial failure. Earlier this month, KalVista had to stop a Phase II trial of its hereditary angioedema drug KVD824 after issues with liver enzymes were detected throughout all three treatment groups. Pereira has been president and CEO of Otsuka sub Visterra since 2013. → Proteomics biotech SomaLogic , which reverse-merged onto Nasdaq with Eli Casdin’s SPAC with a $1.2 billion valuation last April, has tapped Troy Cox as executive chair of the board of directors, taking over from Chuck Lillis , who will remain on the board. Cox formerly served as president and CEO of Foundation Medicine and was SVP and officer at Genentech and held roles at UCB , Sanofi-Aventis and Schering-Plough . → Rocket Pharmaceuticals chief Gaurav Shah is now chairman of the board at Swiss gene therapy developer Anjarium Biosciences , which unveiled a $61 million launch round in September 2021 thanks to such big-name investors as Pfizer and Abingworth . And after joining the board at Oncorus in June, ex- Dicerna CEO Doug Fambrough also has a place in Anjarium’s boardroom. → Cell processing shop Curate Biosciences has reserved space for Shah’s chief technical officer at Rocket, Mayo Pujols , on the board of directors. Pujols was in charge of global manufacturing for liso-cel (now Breyanzi ) as Celgene ’s VP of global CAR-T operations and technology. → Belgian infectious disease biotech ExeVir has appointed Jeanne Bolger to chair the board of directors. After 13 years at GSK, Bolger switched to another pharma giant as VP of scientific licensing at J&J, later becoming the VP of venture investing at Johnson & Johnson Innovation (JJDC) . → Theseus Pharmaceuticals — a TKI player from OrbiMed whose stock $THRX recently hit its nadir practically a year to the day that it joined Nasdaq in a none-too-shocking development in this market — has added Incyte CMO Steven Stein to the board of directors. Stein is a former clinical development exec with GSK and Novartis Oncology . → Geron ’s EVP, corporate strategy and chief commercial officer Anil Kapur is making his way to the board of directors at Verastem Oncology . Kapur is the former head of early assets, biomarkers and external innovation for worldwide oncology commercialization for Bristol Myers Squibb and the ex-CCO at Actinium . → China-based Hangzhou Qihan Biotech has brought on Tony Ho to its board of directors. Ho joins after a four-year stint at CRISPR Therapeutics , where he most recently served as EVP and head of research & development. Ho’s prior experience includes roles as SVP and head of oncology integration and innovation at AstraZeneca , head of neurology and ophthalmology at Merck and co-founder and CSO at Neuronyx . → Following a recent Series C financing round, Inversago Pharma has reeled in Ed Mathers and Nanna Lüneborg to its board of directors. Mathers is a general partner at New Enterprise Associates and has previously served as EVP, corporate development and venture at MedImmune . Mathers currently serves as a director to a host of companies, including Rhythm Pharmaceuticals , Synlogic , Senti Bio , Inozyme , Akouos and Affinia . Meanwhile, Lüneborg is a general partner at Forbion and formerly served a decade-long stint as a partner at Novo Ventures . → The Illinois Biotechnology Innovation Organization ( iBIO ) has added three new faces to its board of directors with the appointments of: Rahul Jerath (senior director, head of oncology business development & acquisitions at AbbVie), Phil Tennant (SVP and head of oncology business unit at Astellas ), and Joe Whalen (SVP, alliances & international business development at Horizon Therapeutics ). Illustration: Kim Ryu for Endpoints News

基因疗法抗体高管变更疫苗并购

2022-10-17

·BioSpace

Qihan Biotech Appoints Tony W. Ho to its Board of Directors

HANGZHOU, China--(BUSINESS WIRE)-- Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today announced the appointment of Tony W. Ho, M.D., to its Board of Directors as an independent director. Dr. Ho is a highly accomplished leader with extensive experience across all phases of Research & Development, including discovery, early and late-stage clinical development, and regulatory throughout his over 20 years of career, and most recently served as Executive Vice President and Head of Research & Development at CRISPR Therapeutics, where he oversaw the company's global research and development efforts across all therapeutic areas. In a period of 4 years at CRISPR Therapeutics, Dr. Ho built a world-class R&D engine and a pipeline of over 10 product candidates. He and his team have brought the first CRISPR-based therapy CTX001, three allogeneic CAR-T (CTX110 (CD19), 120 (BCMA), 130 (CD70)), and the first CRISPR edited pancreatic islet progenitor cells (VCTX210) from research bench to the clinic. Prior to CRISPR Therapeutics, Dr. Ho was SVP and Head of Oncology Integration and Innovation at AstraZeneca and oversaw the development and commercialization of Lynparza and Imfinizi (anti-PD-L1). 10 Phase 3 trials designed under his leadership have now read out positive (Lynparza: SOLO1, SOLO2, SOLO3-1L & PSR Ovarian, OlympiAD-TNBC, POLO-Pancreatic, PAOLA – 1L Ovarian, ProFound 2LmCRC; Imfinizi: Pacific- NSCLC, CASPIAN 1L SCLC, Poseidon 1L NSCLC (IO+IO+CHEMO). He has also successfully repositioned a failed NK3 antagonist for Polycystic Ovary Syndrome (PCOS). Before joining AstraZeneca, Dr. Ho was the head of Neurology and Ophthalmology at Merck, where he led the development and launch of Zioptan and several Phase III programs, including CGRP-RA for migraine, A2a-RA for Parkinson's disease, prostaglandin for glaucoma, and several early programs in neuropathic pain, stroke, Alzheimer's disease. Before Merck, Dr. Ho was the Co-Founder and CSO of Neuronyx, a start-up that developed stem cells for heart failure, immuno-oncology, and islet cells. Dr. Ho completed his B.S. in Electrical Engineering at the University of California, Los Angeles, and received his M.D. from the Johns Hopkins University School of Medicine. He was Assistant Professor at Johns Hopkins, specializing in neuropathy and neuromuscular diseases, and described and elucidated the pathogenesis of a new disease called "acute motor axonal neuropathy (AMAN)." He has published widely in several fields, with over 80 papers. Currently, he serves as an Adjunct Associate Professor of Neurology at the University of Pennsylvania and an Assistant Professor of Neurology at Johns Hopkins University. "I am excited to welcome Tony, who brings a wealth of experience and expertise to Qihan Biotech," said Dr. Luhan Yang, co-founder, and CEO of the Company. "With a particular focus on supervising the company's Research and Development, Tony's leadership and proven track record will be instrumental as we continue to grow and advance our pipeline." "The Company's multiplexable genome editing platform, combined with the team's deep knowledge and research of Natural Killer (NK) cell biology, is the solid cornerstone of Qihan's product innovation," said Dr. Tony Ho. "I am delighted to join Qihan's Board of Directors, and my perspective is to help foster a team's success and develop the off-the-shelf, iPSC-derived NK cell therapy product that is safe and effective for patients worldwide." About Qihan Biotech Qihan Biotech is a biotech company applying genome-editing technology to develop novel cell therapies and organs for transplantation. The company's mission is to use high- throughput, multiplexable genome editing combined with expertise in transplantation immunology to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other complex medical conditions. With a vision to create a world in which cell and organ therapies are universally available to patients, Qihan Biotech has raised two rounds of financing and is advancing its cell therapy programs into IND enabling investigations. Qihan Biotech is headquartered in Hangzhou, China. For more information, please visit the company's website at . Forward-looking Statements This release contains statements including, but not limited to, Qihan’s research development and/or relevant programs, its past, ongoing, and planned research studies, and the potential of Qihan’s research candidate. These and any other statements in this release are based on Qihan management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such statements. These risks and uncertainties include, but are not limited to, the risk that Qihan’s research program may not warrant further development, the risk that results observed in prior studies of Qihan’s research candidates will not be observed in ongoing or future studies involving these candidates, the risk of a delay or difficulties in the developing or transforming of Qihan’s research candidates, the risk that Qihan may cease or delay the research development of any of its candidates for a variety of reasons. Qihan is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in this release as a result of new information, future events, or otherwise. Information concerning therapies and related products contained herein is not intended as medical advice.

基因疗法细胞疗法

100 项与 Neuronyx, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Neuronyx, Inc. 相关的转化医学

登录后查看更多信息